Results 11 to 20 of about 21,457 (218)
Ruxolitinib reverses systemic vasculitis driven by JAK2 V617F–mutated essential thrombocythemia: a case report [PDF]
Frontiers in ImmunologyBackgroundVasculitis associated with myeloproliferative neoplasms is rare, and reports on its treatment are limited. Herein, we report a case of Janus Kinase2 (JAK2) V617F mutation–positive essential thrombocythemia (ET) associated with vasculitis.Case ...
Yutaro Ashida +14 more
doaj +2 more sources
Essential thrombocythemia [PDF]
Orphanet Journal of Rare Diseases, 2007 Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000.
Brière Jean B
doaj +5 more sources
Essential thrombocythemia: a rare disease in childhood
Revista Brasileira de Hematologia e Hemoterapia, 2013 Essential thrombocythemia is an acquired myeloproliferative disorder characterized by the proliferation of megakaryocytes in bone marrow, leading to a persistent increase in the number of circulating platelets and thus increasing the risk for thrombotic ...
Julia Maimone Beatrice +1 more
doaj +2 more sources
Systemic Mastocytosis and Essential Thrombocythemia: Case Report and Literature Overview [PDF]
Medicina, 2019 Mastocytosis is a rare disease in which heightened amounts of mast cells accumulate in the skin, bone marrow, and other visceral organs. Upon activation, mast cells release a wide variety of preformed or newly synthesized mediators which can induce ...
Mauro Cancian +6 more
doaj +2 more sources
Clinical and hematological profile of patients with philadelphia-negative myeloproliferative neoplasms: First report from the Ecuadorian registry [PDF]
Hematology, Transfusion and Cell TherapyIntroduction: Philadelphia-negative myeloproliferative neoplasms are clonal blood disorders characterized by abnormal blood cell production. This study explores the clinical and epidemiological profiles of 111 Ecuadorian patients diagnosed with ...
C Freire +8 more
doaj +2 more sources
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations [PDF]
Haematologica, 2015 The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mutations are mutually exclusive in essential thrombocythemia and support a novel molecular categorization of essential thrombocythemia.
Carla Al Assaf +12 more
doaj +2 more sources
Essential thrombocythemia, hemolytic anemia and hepatic cirrhosis: Could there be an association?
Hematology Reports, 2018 Vascular events are the most common clinical complication of essential thrombocythemia, leading to sign and symptoms of this disease. There are various sign and symptoms of essential thrombocythemia, such as thrombosis in artery or vein, and enlarged ...
Nata Pratama Hardjo Lugito +4 more
doaj +3 more sources
Acute megakaryoblastic transformation from essential thrombocythemia
Human Pathology: Case Reports, 2017 Essential thrombocythemia (ET) is a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by sustained thrombocytosis. Its transformation into acute leukemia is a rare event (5% at 20 years).
Tariq M. Roshan +3 more
doaj +2 more sources
Haematologica, 2019 Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera (PV),
Richard T. Silver, Spencer Krichevsky
doaj +3 more sources
Haematologica, 2008 Background Hereditary thrombocythemia is an autosomal dominant disorder with clinical features resembling sporadic essential thrombocythemia.
Kun Liu +11 more
doaj +2 more sources